Aktuellt
SENASTE
Redeye leaves a comment on the Q2 report published by Alzinova earlier today. Overall, the report was in line with our expectations. However, we are encouraged by the clinical and regulatory progress made as we await the crucial phase Ib study results with ALZ-101. For now, we reiterate our previous fair value range (SEK1 – SEK20) with a base case valuation of SEK10 as we continue to have a positive outlook on the case.
LÄS MER
